Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Wales stories

Jul 8, 2026

AstraZeneca and Daiichi Sankyo Near UK Pricing Agreement for Breast Cancer Drug Enhertu

AstraZeneca and Daiichi Sankyo are nearing a pricing agreement with the UK's National Institute for Health and Care Excellence (NICE) for their breast cancer treatment Enhertu, which could provide access to women in England and Wales with HER2-low breast cancer.

Jul 8, 2026·2 sources
00

Top claims

  • ▪AstraZeneca and Daiichi Sankyo are nearing a pricing agreement with the UK's pricing regulator for the breast cancer drug Enhertu.
  • ▪AstraZeneca CEO Pascal Soriot stated in April that changes to Britain's cost-effectiveness methodology could allow for an acceptable reimbursement price for Enhertu.
  • ▪Enhertu is a breast cancer treatment developed by AstraZeneca and its Japanese partner, Daiichi Sankyo.

Topics

Public healthcareCancer treatmentHealthcare Policy

Related entities

EnglandUnited Kingdom

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 2026·2 sources